Immuno-oncology combinations and beyond
The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals.
The end of the Humira era
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
